{
  "name": "Rare Disease Venture Atlas Agent",
  "description": "Open translational & venture diligence specialist agent anchored on Paired Myelofibrosis Flagships—Clonal JAK2 V617F+ Primary Myelofibrosis (JH2 vs JH1 allosteric selectivity, mutant CALR) and Reversible JAK2-Negative Autoimmune Myelofibrosis (AIMF, 74-80% marrow fibrosis reversal + dual transfusional & IL-6/hepcidin/ferroportin iron overload)—plus 4 comparative hematology/immunology cohorts, non-dilutive grant stacks (SBIR, ARPA-H, Blood Cancer United TAP, MPNRF), 90-day validation plans, and live federated diligence across all 7,000+ orphan diseases.",
  "url": "https://api.rare-disease-atlas.workers.dev/a2a",
  "documentationUrl": "https://rare-disease-atlas.github.io/llms-full.txt",
  "mcpServerUrl": "https://api.rare-disease-atlas.workers.dev/mcp",
  "mcpServerCardUrl": "https://rare-disease-atlas.github.io/.well-known/mcp/server-card.json",
  "provider": {
    "organization": "Rare Disease Venture Atlas",
    "url": "https://rare-disease-atlas.github.io"
  },
  "version": "1.6.0",
  "protocolVersion": "0.3.0",
  "preferredTransport": "JSONRPC",
  "capabilities": {
    "streaming": false,
    "pushNotifications": false,
    "stateTransitionHistory": false
  },
  "defaultInputModes": [
    "text/plain",
    "application/json"
  ],
  "defaultOutputModes": [
    "text/plain",
    "application/json"
  ],
  "skills": [
    {
      "id": "jak2-clonal-myelofibrosis-diligence",
      "name": "Clonal JAK2 V617F+ Myelofibrosis (JH2 vs JH1) Translational Diligence",
      "description": "Analyzes Type I JH1 JAK inhibitor cytopenia & persistence failure modes, mutant-selective JH2 pseudokinase binders/degraders (INCB160058 NCT06313593, PDB 4FVR/6E2Q/8BAK vs WT 4FVP), Type II persistence breakers (AJ1-11095 NCT06343805), mutant CALR biologics, and single-cell bone marrow datasets (GSE144568, GSE122198).",
      "tags": [
        "myelofibrosis",
        "JAK2-V617F",
        "JH2",
        "JH1",
        "CALR",
        "PROTAC",
        "clinical-trials"
      ],
      "examples": [
        "Explain JH2 vs JH1 selectivity in JAK2 V617F myelofibrosis and active NCT trials.",
        "Call get_disease_case_study for jak2-myelofibrosis and design a zero-wet-lab JH2 degrader validation plan."
      ]
    },
    {
      "id": "autoimmune-myelofibrosis-iron-triage",
      "name": "Reversible Autoimmune Myelofibrosis (AIMF) & Dual Iron Overload Positive-Control Triage",
      "description": "Contrasts clonal JAK2+ PMF against reversible JAK2-negative lupus/autoimmune myelofibrosis (AIMF: 74-80% hematologic & marrow fibrosis remission on corticosteroids/rituximab) and dual transfusional + IL-6/hepcidin/ferroportin reticuloendothelial iron overload.",
      "tags": [
        "autoimmune-myelofibrosis",
        "AIMF",
        "lupus",
        "SLE",
        "hepcidin",
        "ferroportin",
        "iron-overload",
        "fibrosis-reversal"
      ],
      "examples": [
        "How does JAK2-negative autoimmune myelofibrosis (AIMF) with lupus suspicion and dual iron overload differ from triple-negative PMF?",
        "Use AIMF as Nature's Positive Control to identify human marrow fibrosis reversal switches."
      ]
    },
    {
      "id": "search-orphan-venture-wedges",
      "name": "Search Orphan Disease Startup Blueprints & 90-Day Validation Plans",
      "description": "Searches concrete rare-disease startup wedges via search_founder_opportunities and generates 30/60/90-day killer-experiment roadmaps via get_90_day_validation_plan across AI/ML drug repurposing, public-health/EHR diagnostics, and venture-philanthropy spinouts.",
      "tags": [
        "rare-disease",
        "venture",
        "biotech",
        "ai-bio",
        "public-health",
        "90-day-plan"
      ],
      "examples": [
        "Search zero-wet-lab computational AI/ML startup wedges under $250K seed budget and generate a 90-day validation plan.",
        "What public-health diagnostic wedges prevent misdiagnosis of Autoimmune Myelofibrosis?"
      ]
    },
    {
      "id": "federated-7000-orphan-disease-scan",
      "name": "Live 7,000-Orphan-Disease Federated Diligence Scan",
      "description": "Queries OpenTargets Platform v4, ClinicalTrials.gov v2, and PubMed live via search_any_orphan_indication for any of 7,000+ orphan diseases, pairing FY2026 FDA Orphan Drug ($4,682,003 PDUFA waiver, 7-yr exclusivity) and Rare Pediatric PRV unit economics against Paired Myelofibrosis Flagships.",
      "tags": [
        "orphan-drug",
        "7000-diseases",
        "OpenTargets",
        "ClinicalTrials",
        "PubMed",
        "PRV",
        "diligence"
      ],
      "examples": [
        "Run search_any_orphan_indication on VEXAS syndrome and Telomere Biology Disorders and benchmark against JAK2 V617F+ and Autoimmune Myelofibrosis.",
        "Evaluate live clinical trial gaps and Rare Pediatric PRV eligibility for Duchenne muscular dystrophy."
      ]
    },
    {
      "id": "non-dilutive-grant-stacking",
      "name": "Orphan Disease Non-Dilutive Capital & Ethical Community Validation",
      "description": "Lists stackable NIH SBIR/STTR, ARPA-H, MPN Research Foundation, Blood Cancer United TAP, CDCN/Every Cure, and FDA OOPD grants (list_non_dilutive_grants) paired with non-extractive patient-community validation pathways (get_validation_communities).",
      "tags": [
        "grants",
        "SBIR",
        "ARPA-H",
        "non-dilutive",
        "patient-advocacy",
        "ethical-validation"
      ],
      "examples": [
        "List non-dilutive grants and ethical validation communities for a seed-stage myelofibrosis AI drug repurposing team."
      ]
    }
  ]
}
